ArticlePloS one2026
HIV/AIDS burden, attributable risk factors, and projections among reproductive-age adults in China, 1990-2035: A GBD 2023 analysis.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHIV/AIDS remains a leading infectious disease burden globally. While highly active antiretroviral therapy has transformed HIV into a manageable chronic condition, contemporary trends and attributable risk factors among reproductive-age adults in China-a critical demographic for epidemic control-remain poorly characterized. This study provides an updated comprehensive assessment of HIV/AIDS burden in this population using Global Burden of Disease Study 2023 data, which incorporates methodological refinements and post-pandemic data not available in earlier versions.
methodsWe extracted age-standardised incidence, prevalence, mortality and disability-adjusted life-years (DALYs) for Chinese adults aged 15-49 years from GBD 2023. Joinpoint regression estimated annual percent change and identified significant trend inflection points. Population attributable fractions were analysed for unsafe sex, drug use, and intimate-partner violence. ARIMA models forecasted burden trends to 2035 with 95% uncertainty intervals.
resultsBetween 1990 and 2023, age-standardised rates increased substantially: incidence +301% (from 0.82 to 3.29 per 100,000), prevalence +774% (4.84 to 42.29), mortality +1,623% (0.13 to 2.24), and DALYs + 1,439% (7.96 to 122.48). Males showed consistently steeper increases than females across all metrics (all p < 0.05). Unsafe sex accounted for 70% of HIV/AIDS mortality in 2023. ARIMA projections indicate that while male incidence will plateau at ~5.0 per 100,000 by 2035, female metrics will continue rising (incidence +21%, prevalence +30%), widening the sex disparity.
conclusionChina's HIV epidemic has transitioned to a chronic disease burden. Notably, this burden shows pronounced sex differences. Mortality is rising among people living with HIV, particularly among women. These trends highlight urgent needs for gender-differentiated prevention strategies. Our findings provide measurable targets for China's National HIV/AIDS Action Plan (2024-2030) and SDG 3.3 monitoring. They further demonstrate how standardized burden estimation supports precision public health.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.